Sector Expert: Vernon Bernardino

FBR & Co.

Image: Vernon Bernardino

Vernon Bernardino is an analyst in FBR & Co.'s life sciences equity research department. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and immunotherapy companies that focus on treatment of cancer, infectious diseases and cell-based therapies targeting inflammatory disorders and vascular diseases. Bernardino brings more than 10 years of experience covering life sciences companies at various financial institutions, including Rodman & Renshaw, UBS and Dawson James. Earlier in his career, Bernardino was a buyside analyst at Nicholas Applegate Capital Management, and founded the strategic advisory group Oceros Advisors LP. Bernardino holds a bachelor's degree from Rutgers University and a master's degree in business administration (finance) from the University of San Diego.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • Abeona Therapeutics Inc.
  • Cytokinetics Inc.
  • Immune Pharmaceuticals Inc.
  • Intercept Pharmaceuticals Inc.
  • NephroGenex Inc.
  • Novavax Inc.
  • Pluristem Therapeutics Inc.
  • Rexahn Pharmaceuticals Inc.

Recent Interviews

The Inflammatory Disease Marketplace Meets the Drug Pricing Controversy: FBR & Co.'s Vernon Bernardino (10/21/15)

Chronic inflammation causes long-term pain and tissue scarring, manifesting in a range of diseases from rheumatoid arthritis to liver cirrhosis. With the introduction of gene therapy and immunotherapeutics, novel strategies targeting inflammatory disorders are being developed, creating hope for patients with no other clinical options. In this interview with The Life Sciences Report, FBR & Co.'s Vernon Bernardino provides insight on companies developing such strategies that also present solid investment opportunities.

Biotechs with Upside Possibilities Target Ebola and Liver Disease: MLV & Co.'s Vernon Bernardino (9/10/14)

Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.

Not All Stem Cells Are Created Equal: Vernon Bernardino (10/3/13)

Biotech companies are fiercely competing to create the newest and best miracle drugs using stem cell technologies. How can an investor spot the potentially victorious outliers amid the chaos of rival scientific claims? The failure rate of new product development in the only recently understood cell space is terrifying, but in this interview with The Life Sciences Report, analyst Vernon Bernardino of MLV & Co. reveals his formula for evaluating the strongest contenders. Bernardino also names five companies with products that may succeed in this new and competitive space.

Recent Quotes

"The data for RNN's supinoxin and RX-3117 are encouraging."

— Vernon Bernardino, FBR & Co. (9/28/15)
more >

"We resume coverage of RNN with an Outperform rating."

— Vernon Bernardino, FBR & Co. (9/1/15)
more >

"RNN's shares are an attractive value proposition."

— Vernon Bernardino, MLV & Co (8/11/15)
more >

"RNN has made progress laying groundwork for initiating advanced studies."

— Vernon Bernardino, MLV & Co (5/12/15)
more >

"RNN's Supinoxin demonstrated potential as a malignant tumor treatment."

— Vernon Bernardino, MLV & Co (4/22/15)
more >

"RNN's antitumor activity has strategic flexibility and untapped potential."

— Vernon Bernardino, MLV & Co (4/20/15)
more >

"We initiate coverage on RNN with a Buy rating."

— Vernon Bernardino, MLV & Co (3/20/15)
more >

"We remain positive and believe NBS10 will advance."

— Vernon Bernardino, MLV & Co (11/18/14)
more >

more comments

"NBS's NBS10 could achieve a peak of 29% share of STEMI patients receiving coronary stents."

— Vernon Bernardino, MLV & Co (11/14/14)
more >

"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach."

The Life Sciences Report Interview with Vernon Bernardino (9/10/14)
more >

"IMNP's bertilimumab is a powerful antibody."

The Life Sciences Report Interview with Vernon Bernardino (9/10/14)
more >

fewer comments

Due to permission requirements, not all quotes are shown.